Health & Fitness
Tue, November 29, 2011Mon, November 28, 2011Sun, November 27, 2011Fri, November 25, 2011Thu, November 24, 2011Wed, November 23, 2011Tue, November 22, 2011Mon, November 21, 2011Sun, November 20, 2011Fri, November 18, 2011Thu, November 17, 2011Wed, November 16, 2011Tue, November 15, 2011Mon, November 14, 2011Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference
//health-fitness.news-articles.net/content/2011/ .. -jaffray-23rd-annual-health-care-conference.html
Published in Health and Fitness on Monday, November 21st 2011 at 5:35 GMT by Market WireTengion to Present at Piper Jaffray 23rd Annual Health Care Conference -- EAST NORRITON, Pa., Nov. 21, 2011 /PRNewswire/ --
Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference
EAST NORRITON, Pa., Nov. 21, 2011 /PRNewswire/ -- Tengion, Inc. (NASDAQ: [ TNGN ]), a leader in regenerative medicine, today announced that Brian Davis, Vice President Finance and Chief Financial Officer of Tengion, will present at the upcoming Piper Jaffray 23rd Annual Health Care Conference on Wednesday, November 30, 2011, at 3:00 p.m. EST.
A live audio webcast of the presentation can be accessed at [ http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TNGN&item_id=4229195 ] or under "Calendar of Events" in the Investors section of the Company's website at [ www.tengion.com ]. A replay of the presentation will be available. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.
About Tengion
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.
SOURCE Tengion, Inc.
[ Back to top ] RELATED LINKS
[ http://www.tengion.com ]
